The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer by Dobrzycka, Bozena et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 49, No. 4, 2011
pp. 631–635
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0086
www.fhc.viamedica.pl
ORIGINAL STUDY
Correspondence address: B. Dobrzycka, Department of
Obstetrics, Gynecology and Obstetrics/Gynecological Care,
Medical University of Bialystok,
Warszawska Str. 15, 15–062 Bialystok, Poland;
tel.: (+ 48 85) 748 88 69, fax: (+ 48 85) 748 88 60;
e-mail: bdobrzycka@gmail.com
The prognostic significance of the
immunohistochemical expression of P53 and BCL-2
in endometrial cancer
Bozena Dobrzycka1, Slawomir J. Terlikowski1, Magdalena Garbowicz2,
Jacek Niklinski2, Lech Chyczewski3, Marek Kulikowski4
1Department of Obstetrics, Gynecology and Obstetrics/Gynecological Care,
Medical University of Bialystok, Poland
2Department of Clinical Molecular Biology, Medical University of Bialystok, Poland
3Department of Pathomorphology, Medical University of Bialystok, Poland
4Department of Perinatology, Medical University of Bialystok, Poland
Abstract: The objective of this study was to verify the frequency of P53 and BCL-2 immunohistochemical ex-
pression in 98 patients with endometrial carcinoma, and to correlate it with clinical stage and patient survival.
A significant difference was found regarding the frequency of P53 expression when comparing type I and II tumors
(23.7% and 54.5%, respectively; p = 0.006). A positive correlation was observed between P53 immunoexpres-
sion and patient survival in type I and II tumors (p = 0.009 and p = 0.036, respectively). BCL-2 expression was
significantly more frequent in early clinical stages in both types of endometrial cancer (p < 0.001 and 0.002) and
correlated with a decrease in overall survival in type I endometrial cancer (p = 0.014). Thus, the prognostic
value of these biomarkers in endometrial cancer needs to be further investigated. (Folia Histochemica et Cytobi-
ologica 2011; Vol. 49, No. 4, pp. 631–635)
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Introduction
Endometrial carcinoma is one of the commonest gy-
necological malignancies. The age-adjusted incidence
rate in Poland is 13.7 per 100,000 women per year
[1]. Acknowledged clinicopathological prognostic
markers used to determine the course of endometri-
al carcinomas include histological type, tumor grade,
depth of myometrial invasion, lymph-node involve-
ment and clinical stage [2]. In the majority of cases,
the neoplasm is histologically diagnosed as an en-
dometrial carcinoma of endometrioid type (type I)
and its stage at the time of diagnosis as type I accord-
ing to the criteria of the International Federation of
Gynecology and Obstetrics (FIGO). The second ma-
jor group of endometrial cancer is histologically clas-
sified as serous carcinoma (type II) [2].
In the past few years, several studies have assessed
the clinical relevance of different biological factors
evaluated in tissue samples from patients with en-
dometrial cancer in order to detect markers capable
of predicting the outcome [3–8]. Several publications
have regarded the TP53 and the BCL-2 genes as pos-
sible markers of endometrial cancer aggressiveness
[9–11]. Some 20–50% of endometrial carcinoma cas-
es show abnormal P53 expression. The expression of
P53, as seen in immunohistochemical analysis, seems
to be related to undifferentiated, aggressive tumors,
with a poor prognosis [6]. BCL-2 expression is rela-
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tively high in the normal endometrium, decreases in
endometrial cancer and has been related to well-dif-
ferentiated endometrial tumors, early-stage disease
and diseases with a good prognosis [9, 10].
The aim of the present study was to estimate the
frequency of P53 and BCL-2 immunohistochemical
expression in patients who have been surgically treat-
ed for endometrial carcinoma, and to correlate this
expression with clinical stage and survival.
Material and methods
Patients and clinical samples. A total of 98 patients with
endometrial cancers (aged 49–72, median value — 61.7
years) treated at the Department of Gynecology Medical
University of Bialystok and the Department of Gynecology
District Hospital in Bialystok between 1999 and 2003, were
included in this study. None of the patients had received
chemotherapy, hormonal therapy or radiation therapy pri-
or to surgery. All patients had primary cancers and were
receiving first treatment. Cases selected in the present study
showed the same stage, both clinically and surgically. All
tumors were staged according to the FIGO criteria. All pa-
tients underwent abdominal hysterectomy and bilateral
oophorectomy. Pelvic and paraaortic lymphadenectomy was
done at stage II (34 cases) and stage III (16 cases). Adju-
vant chemotherapy was added to the treatment for stage
III patients.
Clinicopathological information was obtained from med-
ical charts. Histopathological examination was performed
according to the WHO classification. Representative sam-
ples of hysterectomy specimens were stained with H&E for
light microscopic study and evaluated to confirm a tumor
stage and histological type. Patients were informed and gave
their consent for the study. The protocol was previously ap-
proved by the Bioethical Committee of the Medical Uni-
versity of Bialystok. Follow-up data was completed until
January 2010.
Immunohistochemical analysis. The following primary an-
tibodies were used: monoclonal mouse anti-human P53 pro-
tein, Clone: Do-7; Code M7001 and monoclonal mouse anti-
human BCL-2 oncoprotein, Clone: 124; Code M0887
(Dako, Glostrup, Denmark). All reactions were performed
using positive controls (breast cancer for P53 expression and
tonsils for BCL-2 expression).
After deparaffinization and rehydration, antigen retriev-
al, inactivation of endogenous peroxidase and blocking of
non-specific reactions, the sections were incubated for 2 h
at ambient temperature with a diluted solution of primary
antibodies (1:50 for P53 and 1:100 for BCL-2). Primary
antibody binding was revealed by streptavidin-biotin per-
oxidase complex and diaminobenzidine tetrahydrochloride
(LSAB, Dako, Glostrup, Denmark).
Tumors were considered positive for P53 expression if
10% or more of the nuclei of tumor cells stained brown,
and for BCL-2 expression if 10% or more of the cytoplasm
of tumor cells stained brown.
Statistical analysis. Statistical analysis was performed us-
ing Statistica software version 9.0PL (StatSoft, Inc., Stat-
Soft Polska Sp. z o.o., Poland). A chi-square test was used
to evaluate the relationship between categorical variables.
Fisher’s exact test was used to determine significance be-
tween the two groups. A p-value of < 0.05 was considered
as statistically significant. In addition, survival time was cal-
culated from the date of surgery to the date of death and
survival analysis was performed using the Kaplan–Meier
method.
Results
The tumors were classified as follows: 76 cases were
type I (endometrioid endometrial carcinomas) and
22 cases were type II (19 cases of serous and three of
clear-cell carcinomas). Among patients with type I
endometrial cancer, 43 had tumors classified as stage I,
24 had tumors classified as stage II, and nine had tu-
mors classified as stage III.
The type II tumors were classified as follows: five
cases were in stage I, ten cases were in stage II, and
seven cases were in stage III. All patients were fol-
lowed up. At a median follow-up of 60 (range 1–126)
months, 39 (39.8%) patients had died as a conse-
quence of cancer progression.
In type I tumors, P53 immunoexpression was pos-
itive in 18 cases (23.7%), while BCL-2 immunoex-
pression was positive in 44 cases (57.9%). In type II
tumors, P53 and BCL-2 immunoexpression was de-
tected in 12 cases (54.5%) and eight cases (36.4%),
respectively. The correlations of P53 and BCL-2 im-
munoexpression between these two types of tumors
are summarized in Table 1.
No correlation was found between the frequency
of P53 immunoexpression in both types of tumors and
stages (p = 0.17 and p = 0.084). P53 immunoexpres-
sion was more frequent in type II tumors (p = 0.006).
A statistically significant correlation was found be-
tween the frequency of BCL-2 immunoexpression and
Table 1. Comparison of P53 and BCL-2 immunoexpression
between patients with type I and II endometrial cancer
No. of cases P53 BCL-2
Type I no. (%) 76 18 (23.7) 44 (57.9)
Type II no. (%) 22 12 (54.5) 8 (36.4)
p 0.006 0.041
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the clinical stage of type I and II tumors (p < 0.001
and p = 0.002, respectively) (Table 2).
Among patients with positive P53 immunoexpres-
sion in type I endometrial cancer, the Kaplan–Meier
survival estimates of the 1-year, 5-year, and 10-year sur-
vival rates were 97.4%, 92.1%, and 90.8%, respectively,
while the respective rates among patients with negative
P53 immunoexpression were 97.4%, 93.4%, and 93.4%.
A statistically significant difference was observed be-
tween survival rates over time (p = 0.009) (Figure 1).
In the group with type II endometrial cancer with
positive P53 immunoexpression, the Kaplan–Meier
survival estimates of the 1-year, 5-year, and 10-year
survival rates were 86.4%, 77.3%, and 72.7%, respec-
tively, while the respective rates among endometrial
Table 2. Comparison of P53 and BCL-2 immunoexpression
between patients with type I and type II endometrial cancer
of different FIGO stage
No. of cases P53 no. (%) BCL-2 no. (%)
Type I
Stage
I 43 (56.6) 7 (16.3) 38 (88.4)
II 24 (31.6) 6 (25.0) 5 (20.8)
III 9 (11.8) 4 (44.4) 1 (11.1)
p 0.17 < 0.001
Type II
Stage
I 5 (22.7) 2 (40.0) 5 (100)
II 10 (45.5) 8 (80.0) 3 (42.9)
III 7 (31.8) 2 (28.6) 0
p 0.084 0.002
Figure 1. Kaplan–Meier survival analysis concerning
P53 immunoexpression and cumulative survival in type I
endometrial cancer
Figure 2. Kaplan–Meier survival analysis concerning
P53 immunoexpression and cumulative survival in type II
endometrial cancer
Figure 3. Kaplan–Meier survival analysis concerning
BCL-2 immunoexpression and cumulative survival in type I
endometrial cancer
cancer patients with negative P53 immunoexpression
were 100%, 86.4%, and 84.8%. A statistically signifi-
cant difference was observed between survival rates
over time (p = 0.036) (Figure 2).
In type I endometrial cancer patients with posi-
tive BCL-2 immunoexpression, the 1-year, 5-year, and
10-year survival rates were 96.1%, 94.7%, and 94.7%,
compared to those with negative BCL-2 immunoex-
pression (93.4%, 90.8%, and 89.5%, respectively), and
the differences in survival were significant (p = 0.014)
(Figure 3).
Among patients with positive BCL-2 immunoex-
pression in type II endometrial cancer, the Kaplan–
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–Meier survival estimates of the 1-year, 5-year, and
10-year survival rates were 95.5%, 86.4%, and 86.4%,
respectively, while the respective rates among patients
with negative BCL-2 immunoexpression were 90.9%,
81.8%, and 63.6%. No statistically significant differ-
ence was observed between survival rates over time
(p = 0.737) (Figure 4). The cumulative disease-spe-
cific survival curves of patients grouped according to
P53 and BCL-2 immunoexpression are shown in
Figures 1–4.
Discussion
A recent model of endometrial carcinogenesis re-
vealed that there are two different types of tumor.
Type I tumors develop slowly and progressively as
a result of endometrial hyperplasia in unopposed es-
trogen activity. These tumors are characterized by
sustained BCL-2 expression and late mutations to the
TP53 gene, as confirmed by the low expression of P53
in stages I and II in our study. On the other hand,
type II tumors develop in an atrophic epithelium with-
out estrogen stimulation. They are aggressive and
occur in a distinct biological environment. Gene mu-
tation and P53 protein accumulation are often found
in type II lesions [10, 12, 13].
The presence of P53 mutations in endometrial
cancer has been extensively studied in literature. Ap-
proximately one in three endometrial cancers have
abnormalities of P53 by immunohistochemistry [7, 14–17].
A number of studies have shown that both P53 over-
expression and mutation are associated with poor
prognosis [9, 10, 14, 15, 17]. It is worth noting that
earlier grade 3 endometrioid carcinomas were classi-
fied as type II tumors. Molecular data now exists sug-
gesting that most grade 2, and some grade 3, tumors
have molecular profiles similar to grade 1 tumors [12].
In type II endometrial cancer, approximately 80%
of carcinomas have mutations in P53, implying a role
for its inactivation early in the development of this
aggressive tumor type. This is in contrast to type I, in
which P53 mutations are relatively uncommon and
are largely confined to grade 3 tumors. The exact
mechanism for the cause of this mutation is still un-
clear. After DNA damage, nuclear P53 accumulates
and causes cell cycle arrest by inhibiting cyclin-D1
phosphorylation of the Rb gene and therefore pro-
moting apoptosis. Thus, mutated P53 results in a non-
functional protein that accumulates in the cell and
acts as a double negative inhibitor of the wild-type
P53, leading to propagation of aberrant cells [18].
A much lower P53 mutational rate in type I tu-
mors makes P53 a useful molecular marker that dis-
tinguishes type I from type II endometrial cancers
[19]. Overexpression of tumor P53 protein has been
studied by immunohistochemistry; its prevalence in
endometrial cancer reportedly ranged from 30% to
80%. Several studies have concluded that the exami-
nation of tumor P53 provides independent prognos-
tic information [14, 15], while others have failed to
show such a relationship [7, 16, 17, 20].
In our study, we found that 54.5% of type II tu-
mors and 23.7% of type I tumors expressed P53 and
this difference was statistically significant. In previ-
ous publications, the difference in P53 expression
between these two types of tumors has proved to be
more distinct [5, 14, 17, 21]. We noted an increased
P53 immunoexpression in type II tumors but P53
immunoexpression was not found to be statistically
different when surgical staging was analyzed. Studies
have correlated P53 immunoexpression with a de-
crease in overall survival in patients with endometri-
al tumors [22, 23]. In our study, P53 positivity was
also associated with the risk of death.
BCL-2 immunoexpression was observed in 57.9%
in type I tumors and 36.4% of type II that we ana-
lyzed. The literature describes rates of 30–85%
[9, 16, 24], depending on the selection of patients and
type of lesion. Our study demonstrated a correlation
between BCL-2 immunoexpression and tumor type,
stage and patient survival. Several studies have shown
increased BCL-2 immunoexpression to be associat-
ed with some favorable prognostic factors in type I
tumors in initial stages [9, 10, 24, 25]. In our study,
a statistically significant correlation between BCL-2
and disease free survival was found in type I tumors.
In conclusion, P53 immunoexpression was signif-
icantly more frequent in type II tumors and correlat-
Figure 4. Kaplan–Meier survival analysis concerning
BCL-2 immunoexpression and cumulative survival in type
II endometrial cancer
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ed with a decrease in overall survival in both types of
endometrial cancer. A positive correlation was ob-
served between decreased BCL-2 immunoexpression
and patient survival in type I tumors. Thus, the prog-
nostic value of these biomarkers in endometrial can-
cer needs to be further investigated.
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